{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:48:01Z","timestamp":1794660481625,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08094-y","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T09:27:41Z","timestamp":1774776461000},"page":"3377-3389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Complex-to-manage and treatment-refractory psoriatic arthritis in Argentina: real-world evidence from the RECCAPSO network"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5928-1092","authenticated-orcid":false,"given":"Rodrigo","family":"Garc\u00eda-Salinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Lucas","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Fenucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Abdala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Abdala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Ariel A.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"8094_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic Arthritis. N Engl J Med 376:957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"8094_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N et al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"},{"key":"8094_CR3","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-\u00c1vila DG, Bautista-Molano W, Brance ML, et al (2024) Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis. J Rheumatol jrheum. 51:563\u2013572. https:\/\/doi.org\/10.3899\/jrheum.2023-1172","DOI":"10.3899\/jrheum.2023-1172"},{"key":"8094_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.clinthera.2023.05.010","volume":"45","author":"G Ayan","year":"2023","unstructured":"Ayan G, Ribeiro A, Macit B, Proft F (2023) Pharmacologic treatment strategies in psoriatic arthritis. Clin Ther 45:826\u2013840. https:\/\/doi.org\/10.1016\/j.clinthera.2023.05.010","journal-title":"Clin Ther"},{"key":"8094_CR5","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","volume":"59","author":"B Hag\u00e8ge","year":"2020","unstructured":"Hag\u00e8ge B, Tan E, Gayraud M et al (2020) Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. Rheumatology (Oxford) 59:1818\u20131825. https:\/\/doi.org\/10.1093\/rheumatology\/keaa030","journal-title":"Rheumatology (Oxford)"},{"key":"8094_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.clinthera.2023.04.005","volume":"45","author":"AL Ribeiro","year":"2023","unstructured":"Ribeiro AL, Dullius L, Sartori NS et al (2023) Challenges in the management of Psoriatic Arthritis in Latin America: a systematic review. Clin Ther 45:860\u2013867. https:\/\/doi.org\/10.1016\/j.clinthera.2023.04.005","journal-title":"Clin Ther"},{"key":"8094_CR7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0405","author":"R Garcia-Salinas","year":"2025","unstructured":"Garcia-Salinas R, Ogdie A, Sommerfleck F et al (2025) Establishing centers of excellence for Psoriatic Disease in Latin America: consensus recommendations from the REAL-PANLAR group. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.2025-0405","journal-title":"J Rheumatol"},{"issue":"1","key":"8094_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s42358-024-00414-7","volume":"64","author":"A Lucas Ribeiro","year":"2024","unstructured":"Lucas Ribeiro A, Tessari JA, Lubianca Kohem C et al (2024) Development of a questionnaire to assess the patient perspective regarding challenges in psoriatic arthritis treatment\u2014a mixed-methods study. Adv Rheumatol 64:72. https:\/\/doi.org\/10.1186\/s42358-024-00414-7","journal-title":"Adv Rheumatol"},{"key":"8094_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NM, Welsing PM et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80:31\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344","journal-title":"Ann Rheum Dis"},{"key":"8094_CR10","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00296-023-05349-8","volume":"43","author":"R Garcia-Salinas","year":"2023","unstructured":"Garcia-Salinas R, Sanchez-Prado E, Mareco J et al (2023) Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations. Rheumatol Int 43:1821\u20131828. https:\/\/doi.org\/10.1007\/s00296-023-05349-8","journal-title":"Rheumatol Int"},{"key":"8094_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","volume":"84","author":"D Poddubnyy","year":"2025","unstructured":"Poddubnyy D, Navarro-Comp\u00e1n V, Torgutalp M et al (2025) The assessment of spondyloarthritis international society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis. Ann Rheum Dis 84:538\u2013546. https:\/\/doi.org\/10.1016\/j.ard.2025.01.035","journal-title":"Ann Rheum Dis"},{"key":"8094_CR12","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1007\/s10067-025-07626-2","volume":"44","author":"R Garcia-Salinas","year":"2025","unstructured":"Garcia-Salinas R, Mejia-Maggi N, Ruta S et al (2025) Difficult-to-manage axial spondyloarthritis according to ASAS criteria in Reuma-Check cohort: frequency, predictive factors, and treatment patterns. Clin Rheumatol 44:3959\u20133965. https:\/\/doi.org\/10.1007\/s10067-025-07626-2","journal-title":"Clin Rheumatol"},{"key":"8094_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01329-3","author":"F Proft","year":"2025","unstructured":"Proft F, Ribeiro AL, Singla S et al (2025) Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative. Nat Rev Rheumatol. https:\/\/doi.org\/10.1038\/s41584-025-01329-3","journal-title":"Nat Rev Rheumatol"},{"key":"8094_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003809","volume":"10","author":"S Singla","year":"2024","unstructured":"Singla S, Ribeiro A, Torgutalp M et al (2024) Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open 10:e003809. https:\/\/doi.org\/10.1136\/rmdopen-2023-003809","journal-title":"RMD Open"},{"key":"8094_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae074","author":"AL Ribeiro","year":"2024","unstructured":"Ribeiro AL, Singla S, Chandran V et al (2024) Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatol Adv Pract. https:\/\/doi.org\/10.1093\/rap\/rkae074","journal-title":"Rheumatol Adv Pract"},{"key":"8094_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.10.002","author":"H Marzo-Ortega","year":"2025","unstructured":"Marzo-Ortega H, Harrison SR, Fragoulis GE et al (2025) EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.10.002","journal-title":"Ann Rheum Dis"},{"key":"8094_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251356206","author":"GA Medina","year":"2025","unstructured":"Medina GA, Fenucci M, Magri S et al (2025) Distinctive clinical patterns and management trends in late-onset psoriatic arthritis: data from Argentina\u2019s RECCAPSO registry. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X251356206","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"8094_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"key":"8094_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ard.2025.06.619","volume":"84","author":"H Marzo-Ortega","year":"2025","unstructured":"Marzo-Ortega H, Harrison SR, Fragoulis G et al (2025) POS1269\u2005EULAR points to consider for the definitions of difficult-to-manage and treatment-refractory psoriatic arthritis. Ann Rheum Dis 84:1319\u20131320. https:\/\/doi.org\/10.1016\/j.ard.2025.06.619","journal-title":"Ann Rheum Dis"},{"key":"8094_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10067-024-07267-x","volume":"44","author":"H Xu","year":"2025","unstructured":"Xu H, Wang Z, Xu L, Su Y (2025) Refractory psoriatic arthritis: emerging concepts in whole process management. Clin Rheumatol 44:583\u2013590. https:\/\/doi.org\/10.1007\/s10067-024-07267-x","journal-title":"Clin Rheumatol"},{"key":"8094_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105670","author":"C Philippoteaux","year":"2024","unstructured":"Philippoteaux C, Delepine T, Cailliau E et al (2024) Characteristics of difficult-to-treat axial spondyloarthritis: results of a real-world multicentric study. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105670","journal-title":"Joint Bone Spine"},{"key":"8094_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","volume":"9","author":"FM Perrotta","year":"2022","unstructured":"Perrotta FM, Scriffignano S, Ciccia F, Lubrano E (2022) Clinical characteristics of potential \u201cdifficult-to-treat\u201d patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther 9:1193\u20131201. https:\/\/doi.org\/10.1007\/s40744-022-00461-w","journal-title":"Rheumatol Ther"},{"key":"8094_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Perrotta FM (2023) Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol Ther 10:1119\u20131125. https:\/\/doi.org\/10.1007\/s40744-023-00574-w","journal-title":"Rheumatol Ther"},{"key":"8094_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3899\/jrheum.2024-0101","volume":"51","author":"FM Perrotta","year":"2024","unstructured":"Perrotta FM, Gentileschi S, Scriffignano S et al (2024) Difficult-to-treat concept in psoriatic arthritis: analysis of 2 potential definitions in a large group of patients. A cross-sectional study. J Rheumatol 51:985\u2013990. https:\/\/doi.org\/10.3899\/jrheum.2024-0101","journal-title":"J Rheumatol"},{"key":"8094_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005717","author":"D Currado","year":"2025","unstructured":"Currado D, Trunfio F, Saracino F et al (2025) Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2025-005717","journal-title":"RMD Open"},{"key":"8094_CR26","doi-asserted-by":"publisher","unstructured":"Alp G, Kara M, Cinakli H (2024) Potential difficult-to-treat psoriatic arthritis real-world prevalence and contributing factors. Clin Exp Rheumatol. https:\/\/doi.org\/10.55563\/clinexprheumatol\/pqpzef","DOI":"10.55563\/clinexprheumatol\/pqpzef"},{"key":"8094_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15192418","volume":"15","author":"G Novell","year":"2025","unstructured":"Novell G, Azuaga AB, Alascio L et al (2025) Clinical and ultrasound characteristics of a difficult-to-treat psoriatic arthritis population. Diagnostics 15:2418. https:\/\/doi.org\/10.3390\/diagnostics15192418","journal-title":"Diagnostics"},{"key":"8094_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005785","volume":"11","author":"A Zabotti","year":"2025","unstructured":"Zabotti A, Cabas N, Di Nicola C et al (2025) Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis. RMD Open 11:e005785. https:\/\/doi.org\/10.1136\/rmdopen-2025-005785","journal-title":"RMD Open"},{"key":"8094_CR29","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","volume":"63","author":"KD Vassilakis","year":"2024","unstructured":"Vassilakis KD, Papagoras C, Fytanidis N et al (2024) Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry. Rheumatology 63:2427\u20132432. https:\/\/doi.org\/10.1093\/rheumatology\/keae263","journal-title":"Rheumatology"},{"key":"8094_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/17512433.2025.2577729","volume":"18","author":"R Queiro","year":"2025","unstructured":"Queiro R, Alonso S (2025) Difficult-to-treat psoriatic arthritis: challenges, mechanisms, and future directions. Expert Rev Clin Pharmacol 18:695\u2013699. https:\/\/doi.org\/10.1080\/17512433.2025.2577729","journal-title":"Expert Rev Clin Pharmacol"},{"key":"8094_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20182","volume":"39","author":"D Graceffa","year":"2025","unstructured":"Graceffa D, Sperati F, Lora V et al (2025) Upadacitinib in the treatment of difficult-to-treat psoriatic arthritis. J Eur Acad Dermatol Venereol 39:e138\u2013e140","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8094_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40744-025-00784-4","volume":"12","author":"A Zabotti","year":"2025","unstructured":"Zabotti A, Cabas N, De Martino M et al (2025) Real-world effectiveness of bimekizumab in predominantly difficult-to-treat patients with psoriatic arthritis followed in a combined dermatology\u2013rheumatology clinic: a 24-week multicenter study. Rheumatol Ther 12:961\u2013973. https:\/\/doi.org\/10.1007\/s40744-025-00784-4","journal-title":"Rheumatol Ther"},{"key":"8094_CR33","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.2506241.dtt","volume":"35","author":"AE Dimopoulou","year":"2024","unstructured":"Dimopoulou AE, Vassilakis KD, Fragoulis GE (2024) Difficult to treat psoriatic arthritis: the road so far. Mediterr J Rheumatol 35:513. https:\/\/doi.org\/10.31138\/mjr.2506241.dtt","journal-title":"Mediterr J Rheumatol"},{"key":"8094_CR34","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s10067-023-06605-9","volume":"42","author":"A Kumthekar","year":"2023","unstructured":"Kumthekar A, Ashrafi M, Deodhar A (2023) Difficult to treat psoriatic arthritis \u2014 how should we manage? Clin Rheumatol 42:2251\u20132265. https:\/\/doi.org\/10.1007\/s10067-023-06605-9","journal-title":"Clin Rheumatol"},{"key":"8094_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-020-00161-5","volume":"61","author":"G Citera","year":"2021","unstructured":"Citera G, Bautista-Molano W, Pel\u00e1ez-Ballestas I et al (2021) Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis. Adv Rheumatol 61:2. https:\/\/doi.org\/10.1186\/s42358-020-00161-5","journal-title":"Adv Rheumatol"},{"key":"8094_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05806-4","author":"P Santos-Moreno","year":"2021","unstructured":"Santos-Moreno P, Baraliakos X, Garc\u00eda-Salinas R (2021) Engagement process for patients with spondyloarthritis: PANLAR early SpA clinics project \u2014 centers of excellence. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-021-05806-4","journal-title":"Clin Rheumatol"},{"key":"8094_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C (2019) Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol 15:153\u2013166. https:\/\/doi.org\/10.1038\/s41584-019-0175-0","journal-title":"Nat Rev Rheumatol"},{"key":"8094_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae562","author":"R Garcia-Salinas","year":"2024","unstructured":"Garcia-Salinas R, Magri S, Mareco J et al (2024) Arthralgia with risk of progression to psoriatic arthritis: role of clinical assessments and ultrasound as prognostic factors. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keae562","journal-title":"Rheumatology"},{"key":"8094_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-021-00185-5","volume":"61","author":"R Garcia-Salinas","year":"2021","unstructured":"Garcia-Salinas R, Scarafia S, Sommerfleck F (2021) Letter to the editor re: prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis. Adv Rheumatol 61:26. https:\/\/doi.org\/10.1186\/s42358-021-00185-5","journal-title":"Adv Rheumatol"},{"issue":"12","key":"8094_CR40","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3899\/jrheum.2025-0405","volume":"52","author":"R Garcia-Salinas","year":"2025","unstructured":"Garcia-Salinas R, Ogdie A, Sommerfleck F et al (2025) Establishing centers of excellence for psoriatic disease in Latin America: consensus recommendations from the REAL-PANLAR group. J Rheumatol 52(12):1302\u20131311. https:\/\/doi.org\/10.3899\/jrheum.2025-0405","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08094-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:25:41Z","timestamp":1780982741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08094-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8094"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08094-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial Intelligence tools (ChatGPT, GPT-4, OpenAI) were used to assist with English editing during manuscript preparation. All outputs generated by AI were carefully reviewed and edited by the authors to ensure accuracy and appropriateness.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence"}},{"value":"The dataset generated and analyzed during the current study is not publicly available due to institutional and ethical regulations but is available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open data sharing"}},{"value":"All authors declare they have no others conflict of interest regarding the present study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}